Click here to view online. Add this email to your safelist.
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
16 February 2022
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
